We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Revance Therapeutics, Inc. (Nasdaq: RVNC) today announced new hire grants totaling an aggregate of 104,800 inducement restricted stock units (“RSUs”) to 31 employees. The RSUs vest over four...
Revance Therapeutics, Inc. (NASDAQ: RVNC) today announced that the company will be participating in the following investor conferences. William Blair 44th Annual Growth Stock Conference Chief...
- Total net product revenue (DAXXIFY® and RHA® Collection) of $51.7 million, a YoY increase of 13%. - DAXXIFY® net revenue of $22.1 million, after a reduction of $2.0 million related to a...
DAXXIFY® for the treatment of cervical dystonia is the first and only peptide-formulated, long-lasting neurotoxin that offers the potential to improve duration of symptom control1 Revance has...
Conference Call Scheduled for Thursday, May 9, 2024 at 4:30 p.m. ET. Revance Therapeutics, Inc. (NASDAQ: RVNC), today announced that the company will release first quarter 2024 financial results...
– Two presentations highlighting data on DAXXIFY® for the treatment of cervical dystonia, including a new analysis from ASPEN trials assessing patient-desired retreatment intervals and one...
Revance Therapeutics, Inc. (NASDAQ: RVNC) today announced new hire grants totaling an aggregate of 222,452 inducement restricted stock units (“RSUs”) to 29 employees. The RSUs vest over four...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 2.17 | 4.5445026178 | 47.75 | 49.1 | 43.605 | 765 | 46.5409545 | DE |
4 | 2.665 | 5.63961485557 | 47.255 | 52.99 | 43.605 | 535 | 48.2563048 | DE |
12 | -9.5 | -15.9878828677 | 59.42 | 70 | 43.605 | 382 | 54.52385973 | DE |
26 | -2.08 | -4 | 52 | 70 | 43.605 | 377 | 53.53953009 | DE |
52 | -14.28 | -22.2429906542 | 64.2 | 70 | 34 | 541 | 49.47677074 | DE |
156 | -14.28 | -22.2429906542 | 64.2 | 70 | 34 | 541 | 49.47677074 | DE |
260 | -14.28 | -22.2429906542 | 64.2 | 70 | 34 | 541 | 49.47677074 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions